Ondansetrom Generis (Ondansetron Hydrochloride Dihydrate)

Ondansetron is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical settings.

• Chemotherapy‑induced nausea and vomiting: reduces the incidence and severity of acute and delayed episodes.
• Radiotherapy‑induced nausea and vomiting: provides prophylactic control for patients receiving moderate to high dose radiation.
• Post‑operative nausea and vomiting: lowers the risk of early postoperative emesis following general anesthesia.
• Pregnancy‑related hyperemesis gravidarum (off‑label in some regions): may be used when benefits outweigh risks.
• Anticipatory nausea: helps patients who have learned to associate treatment with nausea.

• Ondansetron selectively blocks the serotonin 5‑HT3 receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By preventing serotonin from binding to these ion‑channel receptors, it interrupts the neural signaling cascade that initiates the vomiting reflex, thereby reducing nausea and emesis across multiple triggers.

Ondansetron is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: occasional bowel slowing.
• Diarrhoea: transient loose stools.
• Fatigue: feeling of tiredness.
• Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects

• Cardiac arrhythmia: QT‑interval prolongation, especially with IV use.
• Severe hypersensitivity: rash, angio‑edema, anaphylaxis.
• Serotonin syndrome: when combined with other serotonergic agents.
• Hepatic enzyme elevation: abnormal liver function tests.
• Neuroleptic malignant‑like syndrome: rare extrapyramidal signs.

When prescribing Ondansetrom Generis, clinicians should consider several safety aspects.

• Cardiac monitoring: assess baseline ECG in patients with known QT prolongation.
• Drug interactions: review concomitant medications that affect cardiac repolarisation.
• Renal impairment: adjust dose in severe renal dysfunction.
• Hepatic impairment: use caution in patients with significant liver disease.
• Pregnancy and lactation: weigh benefits against potential risks.
• Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture and direct sunlight.

Ondansetron can interact with several medicines, altering its safety profile or efficacy.

Major Interactions (Avoid)

• Class I anti‑arrhythmics (e.g., quinidine, procainamide): increase risk of QT prolongation.
• Certain azole antifungals (ketoconazole, itraconazole): potentiate cardiac effects.
• Serotonergic agents (SSRIs, MAOIs, tramadol): raise the possibility of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., erythromycin, grapefruit juice): may raise ondansetron plasma levels.
• CYP2D6 substrates (e.g., metoprolol, codeine): modestly increased exposure.
• Diuretics (e.g., furosemide): can exacerbate electrolyte disturbances that affect QT interval.